Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 1993Arteriosclerosis and Thrombosis A Journal of Vascular BiologyOpen Access

Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does indobufen dose-dependently reduce thromboxane biosynthesis and platelet function in patients with non-insulin-dependent diabetes mellitus?

Population

9 patients with non-insulin-dependent diabetes mellitus (NIDDM)

Comparison

Indobufen 50 mg BID, 100 mg BID, and 200 mg BID… vs Baseline and cross-comparison between doses

Design

RCT, randomized, double-blind

Follow-up

1 week per treatment period

Authors

GDGiovanni Davı̀General CardiologyICIsabella CatalanoMcGill UniversityNCN CustroUniversity of Palermo

Discussion

Loading...

Member takes

Implication

Indobufen supports dose selection for TX inhibition in NIDDM; extends evidence that >95% COX suppression is needed for maximal platelet effects.

Structured PICO

Does indobufen dose-dependently reduce thromboxane biosynthesis and platelet function in patients with non-insulin-dependent diabetes mellitus?

P
Population
9 patients with non-insulin-dependent diabetes mellitus (NIDDM)
I
Intervention
Indobufen 50 mg BID, 100 mg BID, and 200 mg BID for 1 week each
C
Comparator
Baseline and cross-comparison between doses (50 mg BID, 100 mg BID, 200 mg BID)
O
Outcome
Urinary 11-dehydro-TXB2 excretion (index of thromboxane biosynthesis)surrogate

Indobufen dose-dependently inhibits thromboxane biosynthesis and platelet function in NIDDM patients, suggesting that >95% suppression of platelet cyclooxygenase may be needed for maximal in vivo inhibition.

Cite This Study

Davı̀ et al. (1993) studied this question.

synapsesocial.com/papers/6a87d004f762332bf8fe7ff9https://doi.org/10.1161/01.atv.13.9.1346

Topics

Dual antiplatelet therapy
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs1987 · 355 citations
  2. 2Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs1987 · 374 citations
  3. 3Clinical pharmacology of platelet cyclooxygenase inhibition.1985 · 453 citations
  4. 4A Comparison of Two Doses of Aspirin (30 mg vs. 283 mg a Day) in Patients after a Transient Ischemic Attack or Minor Ischemic Stroke1991 · 761 citations
  5. 5The d-Enantiomer Form of Indobufen Totally Accounts for the Anti-Cyclooxygenase and Antiplatelet Activity Ex Vivo and for the Increase in Bleeding Time by Indobufen in Man1992 · 16 citations